According to the United States Attorney's Office, Xanthe Lam, a principal scientist at the Roche Holding AG unit from 1986 until 2017, conspired with her husband and fellow former employee Allen Lam, and John Chan, another former Genentech employee, to steal trade secrets over the course of 5 years related to the biopharmaceutical dornase alfa (Pulmozyme) and some of Roche’s top-selling cancer drugs: rituximab (Rituxan), trastuzumab (Herceptin), and bevacizumab (Avastin).
According to a statement issued October 29 by the United States Attorney’s Office in San Francisco, former Genentech employees were charged with conspiring to steal trade secrets to assist biosimilar developer JHL Biotech.
According to the statement, Xanthe Lam, a principal scientist at the Roche Holding AG unit from 1986 until 2017, conspired with her husband and fellow former employee Allen Lam, and John Chan, another former Genentech employee, to steal trade secrets over the course of 5 years related to the biopharmaceutical dornase alfa (Pulmozyme) and some of Roche’s top-selling cancer drugs: rituximab (Rituxan), trastuzumab (Herceptin), and bevacizumab (Avastin).
JHL is currently in the process of developing biosimilars for all 3 of the branded products. In fact, both of its potential biosimilars for trastuzumab and rituximab are about to enter phase 3 trials, while its potential bevacizumab biosimilar was cleared for a phase 1 trial in February 2018. JHL also indicated in March 2018 that it would commence a phase 1 clinical trial of its dornase alfa biosimilar.
The indictment alleges that Xanthe Lam downloaded, collected, and transferred to Allen Lam and others at JHL “certain confidential Genentech documents relating to the processes by which the company formulated drugs and managed raw materials. Xanthe Lam also allegedly secretly consulted for JHL while still employed at Genentech.”
According to prosecutors, Xanthe Lam also allowed a fourth conspirator, James Quach, employed by JHL, to gain access to Genentech documents in efforts to steal the company’s proprietary manufacturing protocols. Specifically, the indictment alleges that she allowed Quach to gain access to Genentech’s secure document repository from which he subsequently stole the company’s proprietary manufacturing protocols.
“We don’t think the government will be able to sustain the charges,” said Xanthe Lam’s lawyer, William Osterhoudt, Bloomberg reported. “She is a brilliant scientist and has patents in her own name. She has been working hard to develop medicines to help people,” he said.
Separately, Genentech filed a civil suit, making similar allegations, in a San Francisco federal court.
“Dishonest and illegal actions such as these threaten scientific innovation, obstruct fair competition, and undermine the work of our employees and people throughout the industry who act with integrity and in the best interests of patients every day,” a Roche representative told Yahoo Finance on Tuesday.
All 4 defendants were arraigned earlier this week before a federal magistrate judge and pleaded not guilty. If found guilty of trade secret theft, Xanthe Lam, Allen Lam, and Chan face as long as 10 years in prison. Quach could face as many as 5 years. All 4 defendants were released on bond and are due back in court on November 2.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.